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region, there is little diagnostic doubt and few tan-
gible mimics. However, such obviously mixed 
clinical signs may not be apparent at presentation 
(or indeed ever) for a large proportion of patients, 
who are nonetheless considered to form part of 
the wider syndrome of ALS (1). This syndrome is 
currently unifi ed by the post mortem fi nding of 
cytoplasmic inclusions of the protein TDP-43, 
with the notable exception of those with mutant 
 SOD1 gene-associated ALS (approximately 1% of 
 Introduction 
 There is an intense need to establish biomarkers 
sensitive to diagnosis, prognostic stratifi cation and 
disease activity of ALS (Table I). The diagnosis of 
amyotrophic lateral sclerosis (ALS) currently 
depends upon the opinion of an experienced 
neurologist, and the exclusion of potential mimic 
disorders. In the context of progressive weakness, 
where there are typical upper (UMN) and lower 
motor neuron (LMN) signs within the same body 
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 Abstract 
 The last 30 years have seen a major advance in the understanding of the clinical and pathological heterogeneity of amyo-
trophic lateral sclerosis (ALS), and its overlap with frontotemporal dementia. Multiple, seemingly disparate biochemical 
pathways converge on a common clinical syndrome characterized by progressive loss of upper and lower motor neurons. 
Pathogenic themes in ALS include excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinfl ammation, altered 
energy metabolism, and most recently RNA mis-processing. The transgenic rodent, overexpressing mutant superoxide 
dismutase-1, is now only one of several models of ALS pathogenesis. The nematode, fruit fl y and zebrafi sh all offer fresh 
insight, and the development of induced pluripotent stem cell-derived motor neurons holds promise for the screening of 
candidate therapeutics. The lack of useful biomarkers in ALS contributes to diagnostic delay, and the inability to stratify 
patients by prognosis may be an important factor in the failure of therapeutic trials. Biomarkers sensitive to disease activ-
ity might lessen reliance on clinical measures and survival as trial endpoints and reduce study length. Emerging proteomic 
markers of neuronal loss and glial activity in cerebrospinal fl uid, a cortical signature derived from advanced structural and 
functional MRI, and the development of more sensitive measurements of lower motor neuron physiology are leading a 
new phase of biomarker-driven therapeutic discovery. 
 Key words:  ALS ,  biomarkers ,  pathogenesis ,  neuroimaging ,  neurophysiology 
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all cases) in whom the disease is nonetheless clin-
ically indistinguishable (2). The failure of multiple 
drugs tried for the treatment of ALS may in part 
be a function of their application relatively late 
in the course of the disease, given the average 
diagnostic delay of one year (3). It is not yet 
known when the initial pathological changes of 
ALS begin, but it seems likely that the clinical 
manifestations occur signifi cantly downstream of 
what may be rapidly irreversible primary events 
at the cellular level. Earlier diagnosis would 
permit introduction of therapies nearer to these 
initiating events. 
 ALS is usually an apparently sporadic disorder 
and the insidious clinical onset involves symptoms 
common to more benign disorders, which means 
that a signifi cant proportion of the diagnostic 
latency may remain inaccessible. At the time of 
diagnosis, however, there is additional value in 
identifying biomarkers sensitive to the recognized 
variation in progression rate. Although the median 
survival from symptom onset in ALS is less than 
three years, the second half of the survival curve is 
longer, and beyond a decade for at least 5% of 
patients. The presence of relatively  ‘ pure ’ UMN or 
LMN clinical signs is associated with longer sur-
vival (4,5), with the rare UMN-only variant pri-
mary lateral sclerosis consistently at the extreme 
end of long survival. However, such clinical fi nd-
ings cannot be reliably used prognostically in isola-
tion. A quantifi able prognostic measure might also 
be used to stratify patients within clinical trials to 
detect meaningful benefi t in the shortest time. 
Knowledge of an individual patient ’ s course at the 
time of diagnosis would facilitate effective care 
planning and resource targeting. 
 Finally, biomarkers sensitive to disease activity 
are the most needed. At present, clinical trials in ALS 
generally rely on tracheostomy-free survival, func-
tional status such as the revised ALS Functional Rat-
ing Scale (ALSFRS-R), or both, as the primary 
outcome measures. Such trials are lengthy (12 – 18 
months typically) and may be prohibitively costly. A 
number of methods have been proposed to optimize 
and shorten such studies (6), but a robust, quantita-
tive monitoring biomarker would have obvious value 
in this regard. 
 Biological themes 
 With the linking of familial ALS to several appar-
ently disparate genes, it seems increasingly likely that 
ALS represents a common fi nal endpoint. A deeper 
understanding of the common molecular pathways 
involved in ALS pathogenesis would facilitate the 
identifi cation of biomarkers. Three genes linked to 
familial ALS in recent years, namely  TARDBP ,  FUS 
and  C9orf72 , indicate a potentially pivotal role for 
RNA mis-processing in the pathogenesis of ALS (see 
Al-Chalabi et  al., companion paper). Downstream of 
these events, cellular biological studies over the last 
two decades have led to the development of multiple 
interconnected pathogenic themes in ALS (7). 
 Excitotoxicity 
 Excitotoxicity encapsulates a process of neuronal 
death ultimately mediated by cellular calcium infl ux, 
triggered via excessive stimulation of receptors for 
glutamate. The fi nding of raised levels of glutamate 
in the CSF in ALS (8), with a sensitivity of only 40% 
in a later study and correlation with disease severity 
(9), provides support for this. 
 The astrocytic glutamate transporter EAAT2 is 
responsible for the clearance of synaptic glutamate, 
and its knockout in transgenic mice results in neu-
ronal death (10). Reduced levels of spinal cord 
EAAT2 protein have been noted in end-stage rodent 
transgenic models of ALS (11,12), with abnormali-
ties of EAAT2 protein expression demonstrable in 
up to 80% of human post mortem brain and spinal 
cord tissue (13). EAAT2 receptor dysfunction has 
been directly linked to mutant (but not wild-type) 
SOD1 in the presence of hydrogen peroxide (14). 
Overexpression of EAAT2 in mutant  SOD1 trans-
genic mice then delayed the onset of motor defi cits 
(15,16). This role for astrocytes supports the view 
that motor neuron degeneration in ALS is not cell-
autonomous. Although the exact mechanism of 
action is uncertain, the only disease-modifying drug 
in ALS to date, namely riluzole, appears to have 
broadly anti-glutamatergic activity (17). 
 Glutamate acts through inotropic (NMDA, 
AMPA and kainate) and metabotropic receptors 
(MGluRs), and the relative contribution of these to 
 Table I. Types of biomarker in ALS, their value and the current gold standards. 
Biomarker type Value Current benchmarks
Diagnostic Initiate therapy earlier;
 Exclude ALS
Neurological history  & examination
 Electromyography (Revised El Escorial/Awaji criteria) 131 
Prognostic  Identify patterns of progression:
 1. Improved stratifi cation in therapeutic trials
 2. Timely intervention and optimal care 
e.g. gastrostomy, non-invasive ventilation, 
cognitive support
Diagnostic latency
 Neurological evaluation (e.g. clinical phenotypes)
 Cox modelling of clinical variables 132,133 
Monitoring  Identify ineffective drugs earlier Revised ALS Functional Rating Score 134 
 (Electrical impedance myography emergent 102 )
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ALS pathogenesis remains uncertain. The develop-
ment of novel selective positron emission tomogra-
phy (PET) ligands may provide clarifi cation. It is 
possible that excitotoxicity arises in ALS as a result 
of wider  ‘ upstream ’ impairments of energy metabo-
lism in ALS so that  ‘ normal ’ levels of glutamate 
become toxic. There is also a body of evidence, 
including from in vivo neuroimaging, indicating an 
overall loss of neuronal inhibitory infl uence in ALS, 
perhaps through a primary interneuronal dysfunc-
tion, resulting in excitotoxicity through less balanced 
glutamatergic activity (18). 
 Oxidative stress 
 Oxidative stress arises from an alteration in the bal-
ance between the generation of reactive oxygen spe-
cies (ROS) and their removal, together with the 
ability of the biological system to remove or repair 
ROS induced damage. The cumulative effect of oxi-
dative stress in aged non-replicating neurons, may be 
one important factor that tips the balance of homeo-
static control mechanisms from an ability to cope 
with a toxic insult such as the presence of a disease-
causing mutation, into a vicious cycle of cellular 
injury culminating in neuronal death and the onset 
of neurodegeneration in middle or later life. Oxida-
tive stress causes structural damage (including DNA 
(19)) and also changes in redox-sensitive signalling 
pathways. The initial interest in the role of oxidative 
stress in ALS (20) was given new impetus with the 
discovery that mutations in  SOD1 , which encodes a 
major anti-oxidant defence protein, accounted for 
approximately 20% of cases of familial ALS (21). It 
is clear that oxidative stress interacts with and poten-
tially exacerbates other pathophysiological processes 
contributing to motor neuron injury, including exci-
totoxicity, mitochondrial impairment, protein aggre-
gation, endoplasmic reticulum stress and alterations 
in signalling from astrocytes and microglia. Several 
potential markers of free radical damage have been 
found in the CSF and blood from ALS patients 
(reviewed in (22)), and also in urine (23). 
 Cellular ROS are generated as by-products of 
aerobic metabolism, predominantly due to leakage 
of electrons from the mitochondrial respiratory 
chain, but with contributions from other intracel-
lular enzyme systems including xanthine oxidase 
and cytochrome P450. ROS that are initially formed 
such as superoxide and hydrogen peroxide may 
undergo further reaction to produce more potent 
oxidant species including peroxynitrite and hydroxyl 
radicals. Biochemical indices of oxidative damage 
to proteins, lipids and DNA in excessive quantities 
compared to controls, can be found in post mortem 
tissue from apparently sporadic and  SOD1 -related 
familial cases. Oxidative damage to RNA species 
has also been documented, adding to the evidence 
that alteration in mRNA processing is an impor-
tant pathophysiological mechanism in ALS (24). 
Indices of oxidative damage are also present in cel-
lular and murine models of  SOD1 -related ALS, and 
interestingly the SOD1 protein itself appears to be 
particularly susceptible to oxidative post-transla-
tional modifi cation. The recent development of cel-
lular models of mutant TDP-43-related ALS 
indicates that the presence of mutant TDP-43 also 
provokes oxidative stress within motor neuronal 
cell lines (25). 
 Sources of oxidative stress in ALS have been 
investigated most thoroughly in mutant SOD1 
(mSOD1) models, where several aberrant oxidative 
reactions have been proposed. However, enzymati-
cally inactive SOD1, depleted of copper loading, is 
still capable of causing motor neuron degeneration, 
and mSOD1 may cause oxidative stress by mecha-
nisms beyond its own catalytic activity (26). mSOD1 
within microglia increases superoxide production by 
NADPH oxidase (Nox) enzymes. SOD1 stabilizes 
Rac1-GTP in the activated Nox2 complex, and 
mutant SOD1 locks Rac1 into its active state, with 
resultant prolongation of ROS production (27). 
Nox2 expression is increased in mSOD1 mice and 
human ALS, and survival of SOD1-G93A mice is 
extended by knock-out of either Nox1 or Nox2. The 
transcription factor Nrf2 (nuclear erythroid-2-
related factor2) is a master regulator of the anti-
oxidant response and responds to oxidative stress by 
binding and up-regulating anti-oxidant response 
element genes. Recent evidence has emerged that 
Nrf2-ARE signalling may be dysregulated in models 
of SOD1-related ALS and in the CNS of ALS 
patients (28). 
 A meta-analysis of therapeutic interventions in 
the mSOD1 mice up to 2007 concluded that anti-
oxidant therapies were the class of drug most effec-
tive at improving survival (29). In human ALS, 
anti-oxidants have not yet shown benefi t, although 
the reported trials have often been of suboptimal 
design, and new in vitro screening methods may be 
able to generate future candidates (30). 
 Mitochondrial dysfunction 
 Mitochondria are critical for cell survival, acting as 
an energy source of the cell, buffering intracellular 
calcium, and regulating apoptosis. Damage to mito-
chondria selectively within tissues affected in ALS 
has been widely observed, especially in inherited dis-
ease caused by mutations in SOD1. Mitochondrial 
abnormalities may be a trigger or a consequence of 
the neurodegenerative process and the precise mech-
anisms remain uncertain (31,32). Mutant SOD1 is 
localized in mitochondria, and accumulates on the 
outer membrane and inside the intermembrane 
space (33). Mutant SOD1 and other mutant pro-
teins, such as TDP-43, may cause mitochondrial 
dysfunction by affecting the expression of mitochon-
drial proteins involved in energy metabolism. Mito-
chondria can also be affected by external SOD1 
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interfering with signalling and transport of the organ-
elles. Key surface components inhibited by misfolded 
mSOD1 include the following: 
 the voltage-dependent anion channel (VDAC1),  •
the conductance of which is inhibited (34); 
 the translocase of the outer membrane (TOM)  •
transport complex, which is responsible for the 
import into mitochondria of over 1000 pro-
teins made in the cytoplasm (35); 
 Bcl2, an anti-apoptotic protein normally asso- •
ciated with mitochondria (36). 
 As a consequence of mSOD1 damage, mitochon-
dria are non-uniformly distributed along axons of 
motor neurons (37). 
 The selective association of mSOD1 with mito-
chondria in cells of affected tissues remains uncer-
tain, as is whether differences in mitochondria or 
cytoplasmic components (e.g. chaperones) may be 
responsible for tissue-specifi c abnormalities of pro-
tein folding. Drugs targeting mitochondrial proper-
ties (e.g. calcium conductance, biogenesis, fi ssion, 
fusion, or transport) might provide therapeutic ben-
efi t. Mitochondrial modulators are a new class of 
potential therapeutic. Olesoxime promotes survival of 
mutant motor neurons in vitro (38), possibly by bind-
ing to the mitochondria, targeting VDAC and the 
benzodiazepine receptor. However, a recent human 
phase III study of olesoxime in ALS proved negative. 
Dexpramipexole is a mitochondrial  ‘ membrane sta-
bilizer ’ (39,40), but a human phase III study in ALS 
also proved negative. 
 Neuroinfl ammation 
 Infl ammatory mechanisms and immune reactivity 
are hypothesized to play a role in the pathogenesis 
of ALS (41). In experimental models, the progres-
sion of ALS has been linked to microglial cell/
macrophage activation in the spinal cord. Studies in 
patients with ALS have found elevated markers of 
infl ammation (CRP, interleukin-6 and 13, mac-
rophage chemotactic protein-1 (MCP-1)) (42). Lev-
els of MCP-1 and other chemokines have also been 
detected in the CSF of ALS patients (43,44). Such 
proteins may contribute to the amplifi cation or 
possibly initiation of infl ammation during ALS. 
Additionally, systemic macrophage activation and 
alteration of macrophage surface markers have 
been linked to disease progression (45). Donor mac-
rophages were present at sites of neuron loss after 
bone marrow transplantation, suggesting an ongoing 
migration of blood monocytes in patients with ALS 
(46). Macrophage activation markers in ALS blood 
are similar to those identifi ed in the blood of patients 
with AIDS dementia where macrophages invading 
the CNS have been proven to induce neurodegen-
eration. Studies with Neuraltus Pharmaceuticals 
NP001, a small molecule regulator of macrophage 
activation in the  SOD1 mouse model, demonstrated 
longer survival compared with controls (19 days, 
 p    0.01) and slowing of the decline in neurological 
score. Phase II studies in humans are currently 
underway. 
 Altered energy metabolism 
 Studies in animal models have convincingly dem-
onstrated that whole body energy physiology is 
impaired in ALS, and that this contributes to 
motor neuron degeneration (47,48). In patients, 
much of the evidence that similar events occur is 
correlative. Most importantly, body mass index 
and overall nutritional status at disease onset 
appear to be strong predictors of survival of patients 
(49,50). Circulating blood lipids are positively cor-
related with survival (51,52) or functional status 
(53). Whether these statistical associations might 
translate into a sensitive and specifi c biomarker 
awaits further investigation. Multiple confounders 
might blur the sensitivity and specifi city of such 
markers. First, dysphagia as a consequence of bul-
bar involvement, has a strong impact on nutritional 
status, and is on its own a sign of poorer prognosis. 
Secondly, impaired glucose tolerance has been 
observed in ALS patients, and it is unknown 
whether abnormalities in glucose metabolism 
infl uence survival in ALS. Finally, regional and 
national dietary specifi cities are very likely to have 
strong infl uence on blood lipids and nutrition, and 
may confound the observed effects. Metabolomic 
studies in the blood of ALS patients and animal 
models might delineate a core set of metabolites 
that could be useful as biomarkers. A recent 
metabolomics study identifi ed altered metabolites 
indicative of disrupted mitochondrial function and 
increased carbohydrate and lipid metabolism in 
ALS patients (54). Alternatively, imaging methods, 
in particular MRI of adipose tissues (55), DEXA-
scan or CT may help to determine whether energy 
stores provide a biomarker related to energy 
metabolism. 
 Disease models 
 For human neurodegenerative diseases it is not cur-
rently possible to study cellular pathological pro-
cesses in real time, or safely and repeatedly remove 
tissue for analysis. The ability to study cellular 
molecular processes, identify key pathways for inter-
vention, and assess multiple candidate therapies over 
short periods of time, depends on the development 
of disease models. The ability to express both wild-
type and mutant human genes in non-human cells 
and transgenic animals has provided a variety of pos-
sibilities for modelling many neurodegenerative dis-
orders, including ALS (56,57). The discovery of 
linkage to the  SOD1 gene of some cases of familial 
ALS led rapidly to the creation of an overexpressing 
mutant  SOD1 transgenic mouse (58). This and other 
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models are summarized in Table II. Such models do 
not, as yet, capture pathogenesis at a systems level, 
and no one model has yet been able to reproduce all 
of the pathological and behavioural features of ALS. 
Nonetheless, they have provided a valuable platform 
for testing many of the pathogenic hypotheses out-
lined earlier in this article, with hope for the future 
development of assays for high-throughput screening 
of therapeutic candidates. 
 Induced pluripotent stem cells 
 The generation of motor neurons from induced 
pluripotent stem cells (iPSCs), in turn derived 
from the skin fi broblasts of ALS patients (59), has 
marked a major advance in modelling pathogenesis 
in ALS, with potential for high-throughput thera-
peutic assessments. Encapsulated by the phrase 
 ‘ disease in a dish ’ , iPSCs carrying the  TDP-43 
 ‘ M337V ’ mutation have already been shown to 
reproduce several key aspects of TDP-43-related 
proteinopathies, including aggregate formation and 
reduced cell survival (60). The ability to generate 
not only motor neurons but also other non-
neuronal cell types (including astrocytes, oligoden-
drocytes, microglia), will allow for versatility in 
teasing out cell-specifi c contributions to disease 
development. iPSCs from patients with familial 
ALS have already been made available to research-
ers at the NINDS Repository, thus allowing for 
the study of ALS arising from numerous  SOD1 , 
 FUS , and  FIG4 mutations. 
 However, a number of challenges remain with 
regard to human iPSC uses for investigation into 
ALS biology. Currently, the long periods of time 
required to generate human neural cells (for exam-
ple, astrocytes) results in signifi cant expense and 
often complex experimental paradigms. Because 
iPSCs are derived from individual patients, careful 
assessment of the sample sizes studied should be 
considered before broad conclusions can be made 
about disease from a single iPSC source. The impact 
of the patients ’ age on the resulting iPSC remains 
unclear. If used to screen for potentially relevant 
ALS drug targets, standardization of cell lines across 
laboratories will be important for validation of drug 
effects. Future aims include the development of 
more complex integrated structures, for example the 
neuromuscular junction using muscle and neuronal 
cell cocultures (61). 
 Despite these challenges, it is likely that more 
effi cient derivation of iPSC will be developed, thus 
shortening the time and expense currently associ-
ated with creating iPSC lines. As sources of iPSC 
become more readily available to the research com-
munity, investigators with a wide range of research 
interests will be able to draw on a range of ALS 
genotypes and phenotypes thus allowing for the 
identifi cation of new ALS relevant disease targets for 
therapeutics. M
od
el
S
pe
ci
fi 
cs
A
L
S
-l
ik
e 
pa
th
ol
og
y
P
ot
en
ti
al
ly
 r
el
ev
an
t 
ph
ys
ic
al
 f
ea
tu
re
s
A
d
va
nt
ag
es
D
is
ad
va
nt
ag
es
K
ey
 r
ef
er
en
ce
s
D
og
 ‘ C
an
in
e 
d
eg
en
er
at
iv
e 
m
ye
lo
pa
th
y ’
 :
  P
em
br
ok
e 
W
el
sh
 c
or
gi
, 
B
ox
er
, 
R
ho
d
es
ia
n 
ri
d
ge
ba
ck
, 
G
er
m
an
 
S
he
ph
er
d
, 
 &
  C
he
sa
pe
ak
e 
B
ay
 
re
tr
ie
ve
r 
al
l 
ho
m
oz
yg
ou
s 
fo
r 
S
O
D
1 
 ‘ E
40
K
 ’  
m
is
se
n
se
 m
u
ta
ti
on
  L
at
er
al
 c
or
d 
w
h
it
e 
m
at
te
r 
m
ye
li
n 
an
d 
ax
on
al
 l
os
s;
  N
eu
ro
n
al
 c
yt
op
la
sm
ic
 i
n
cl
u
si
on
s 
bi
n
d
in
g 
an
ti
-S
O
D
1 
an
ti
bo
d
ie
s
A
du
lt
-o
n
se
t 
pr
og
re
ss
iv
e 
sp
as
ti
c 
m
ye
lo
pa
th
y 
af
fe
ct
in
g 
pe
lv
ic
 g
ir
d
le
, 
le
ad
in
g 
to
 e
ve
nt
u
al
 
fl 
ac
ci
d 
qu
ad
ri
pa
re
si
s
S
im
il
ar
 t
o 
hu
m
an
 
S
O
D
1-
re
la
te
d 
A
L
S
 i
n 
b
ei
n
g 
a 
d
el
ay
ed
 
ad
u
lt
-o
n
se
t 
d
is
or
d
er
E
th
ic
al
 c
on
ce
rn
s,
 
av
ai
la
bl
it
y 
an
d 
in
fr
as
tr
u
ct
u
re
 i
ss
u
es
; 
lo
n
g 
la
te
n
cy
 t
o 
sy
m
pt
om
s;
 l
im
it
ed
 
re
le
va
n
ce
 t
o 
n
on
-
S
O
D
1-
re
la
te
d 
A
L
S
 14
7  
M
on
ke
y
M
ac
ac
a 
fa
sc
ic
ul
ar
is
 o
ve
r-
ex
pr
es
si
n
g 
hu
m
an
 T
D
P
-4
3 
vi
a 
ad
en
ov
ir
u
s 
to
 c
er
vi
ca
l 
co
rd
C
yt
op
la
sm
ic
 m
is
lo
ca
li
za
ti
on
 o
f 
T
D
P
-4
3
; 
cy
st
at
in
-C
 p
os
it
iv
e 
ag
gr
eg
at
es
P
ro
gr
es
si
ve
 m
ot
or
 
w
ea
kn
es
s 
of
 d
is
ta
l 
u
pp
er
 l
im
b
s 
w
it
h 
fa
sc
ic
u
la
ti
on
 a
n
d 
w
as
ti
n
g
C
lo
se
st
 s
pe
ci
es
 t
o 
hu
m
an
s 
ph
ys
ic
al
ly
 a
n
d 
b
eh
av
io
u
ra
ll
y
M
aj
or
 e
th
ic
al
 c
on
ce
rn
s 
an
d 
in
fr
as
tr
u
ct
u
re
 
is
su
es
; 
li
m
it
ed
 
re
le
va
n
ce
 t
o 
 ‘ s
lo
w
ly
-
d
ev
el
op
in
g ’
  h
u
m
an
 
A
L
S
 14
8  
T
ab
le
 I
I.
 (
C
on
tin
ue
d
)
  Mechanisms, models and biomarkers in ALS   25
 Tissue and fl uid biomarker sources 
 Biofl uids 
 The range of human biofl uids useful in proteomic 
studies to identify an ALS biomarker  ‘ signature ’ , 
includes CSF, blood, urine, and saliva (62). CSF is 
an excellent biofl uid for biomarker discovery due to 
its approximation to the cells and brain and spinal 
cord regions exhibiting cell death during ALS. Blood, 
while more accessible, has greater protein complex-
ity with greatly reduced concentrations, compared to 
CSF, of those proteins fundamentally involved in 
neuronal function. 
 During the past decade there has been a large 
increase in the number of ALS biomarker studies 
using CSF as well as blood (22). Most of these stud-
ies have examined changes of individual proteins in 
the CSF of ALS versus healthy control or other neu-
rologic disease subjects, typically using a gel-based 
system or ELISA (63). However, most are limited by 
the number of samples used in the analysis, choice 
of control subjects, and typically the lack of verifi ca-
tion in a separate cohort of patients. A number of 
more recent studies have used mass spectrometry or 
cytokine profi ling to identify panels of candidate 
protein biomarkers in the CSF (43,64). Metabolo-
mic approaches have been used to explore metabolic 
differences between ALS and control subjects in 
CSF and serum (54,65  –  67). Early changes in patient 
metabolism and protein levels or post-
translational modifi cations offer a means to both 
identify ALS at an early stage and to develop bio-
markers to follow during disease progression. 
 At present, CSF candidate biomarkers in ALS 
can be grouped into those that refl ect neuronal loss 
and those indicative of neuroinfl ammatory (glial) 
processes. For the former, neurofi laments have been 
the most reproducible (68  –  70). CSF TDP-43 
appears to fall with disease progression in typical 
ALS (71), with lower values found in cases of ALS-
FTD (72). The signifi cance of fi nding reduced CSF 
transthyretin and cystatin C in ALS is uncertain 
(64). The latter is the essential constituent of the 
 ‘ pathognomonic ’ Bunina body inclusion seen histo-
pathologically in ALS and has been detected at 
increased levels in ALS plasma (73). 
 While several molecules linked to neuroinfl am-
matory pathways have been reported as increased in 
ALS patient CSF, each has limited sensitivity in iso-
lation and many studies have not been reproduced. 
A panel of cytokines, specifi cally interleukins 2, 6, 
10, 15 and granulocyte-monocyte colony stimulating 
factor (GM-CSF) was nearly 90% accurate in dis-
tinguishing ALS patients from healthy controls (43). 
Other studies have also supported the concept of 
combining markers to improve accuracy, most rece-
ntly the ratio of CSF phosphorylated neurofi lament-
heavy chain and complement C3, achieving even 
higher accuracy (74). CSF based biomarkers may be 
useful to aid in the diagnosis of ALS, but may have 
better applications in monitoring drug effects in 
clinical trials and as prognostic indicators of disease 
(73,75). Further studies, involving samples from 
mimic disorders rather than healthy controls, and 
serial samples from ALS patients, are required 
to validate the candidate diagnostic biomarkers 
and fully explore their utility in therapeutic trials. 
An important step has been to both recognize 
the potential variability in sample quality due to 
differences in acquisition and storage (76), and to 
establish international consensus on standard oper-
ating procedures (77). 
 Muscle 
 Skeletal muscle may represent a valuable source of 
biomarkers in ALS. This tissue is one of the most 
severely affected by the disease, with progressive 
denervation and atrophy, and it is easily accessible 
to biopsy. The only muscle biomarker that has been 
tested prospectively is the axon repellant Nogo-A. 
Nogo-A is strongly expressed in ALS muscles, is cor-
related with ALSFRS and prospectively identifi es 
patients affected with lower motor neuron disease 
that will progress to ALS (78  –  80). However, the 
specifi city of this increased expression has been 
questioned. A combination of biomarkers might 
solve the problem of specifi city. Muscle transcrip-
tome analyses have identifi ed a number of potential 
candidates correlated with disease severity (81). 
There are two potential limitations of muscle bio-
markers. First, muscle biopsy is invasive and as a 
consequence longitudinal studies are very diffi cult. 
Secondly, muscle beds are very differentially involved 
among patients. The different sites of onset, as well 
as the heterogenous spreading, make it diffi cult to 
standardize the choice of the site of muscle biopsy. 
In this respect, the future of muscle biomarkers 
might be to identify a set of muscle derived proteins 
or peptides that enter the circulation. Such muscle-
derived blood biomarkers could be useful tools to 
evaluate disease progression and severity in ALS 
patients in a manner similar to creatine kinase for 
myopathies. 
 Skin 
 The skin is an acknowledged part of the disease 
process in ALS, both in experimental models (82) 
and humans (83  –  85). Because this organ is easily 
accessible and at least some of the biochemical 
alterations are related to fi ndings in the CNS 
(82,83), the skin is a principal resource of biomark-
ers for diagnosis, staging, and evaluation of therapy. 
The most striking fi nding is an apparently selective 
elevation of the MMP-9 in the skin and spinal cord 
of experimental animals and in human skin and the 
CSF (82,83). These fi ndings are consistent with 
previous observations of increased collagen degra-
dation, in particular collagen types I and IV, in the 
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skin of ALS patients (84). The pathogenic steps 
responsible for these observations remain to be elu-
cidated; however, free radical damage and infl am-
mation are possible mechanisms. A further discovery 
was that small distal epidermal nerve fi bers are 
affected in ALS (85), indicating the presence of a 
small fi ber neuropathy. The pattern of changes 
refl ects the concept of a distal axonopathy and paves 
the way for mechanistic studies of cytoskeletal alter-
ations and axonal transport. 
 Post mortem tissues 
 While post mortem spinal cord, brain or muscle tis-
sue may not provide the optimal resource for bio-
marker discovery efforts, they are especially important 
to help identify the cell types that express each can-
didate biomarker, as well as their relationship to the 
pathophysiology of the human disease. Increased 
efforts to collect ALS and appropriate control post 
mortem tissues become more crucial as the multi-
tude of candidate biomarkers identifi ed in the above 
mentioned biofl uids and tissue biopsies will require 
proper characterization and correlation to ALS 
pathology. In addition, recent studies have shown 
that neural progenitor cells can be cultured from 
ALS post mortem tissues and used to generate astro-
cytes to investigate astrocyte derived cell signalling 
that infl uences motor neuron survival (86). Given 
the low numbers of banked ALS tissues at any one 
site, standardized collection and storage procedures 
for ALS post mortem tissues must be established to 
permit use of tissues obtained across multiple sites. 
 Neurophysiology biomarker sources 
 EMG and MUNE 
 Neurophysiological testing has been an important 
component of the diagnostic evaluation of patients 
with motor neuron disease since the demonstration 
that axon loss and consequent reinnervation could 
be measured using electromyography (EMG) (87). 
While classical EMG and nerve conduction studies 
are still incorporated into diagnostic criteria for 
ALS (El Escorial), these techniques have not proved 
effective in monitoring disease progression or 
assessing effects of treatment. Motor unit number 
estimation (MUNE) is a tool that was developed 
for this purpose. The technique and theoretical 
basis for MUNE is quite simple; a maximum 
response amplitude, which is generated by activa-
tion of all motor units in the muscle, is recorded, 
from which an estimate of individual motor unit 
number is generated by dividing the maximum 
response amplitude by an estimate of single motor 
unit amplitude. Many techniques for estimating the 
average amplitude of single motor units have been 
suggested; most have been limited by sampling bias, 
and lack of reproducibility (88). 
 Recently, a modifi cation of earlier described 
techniques was introduced and studied in a natural 
history study of patients with ALS (89). Multipoint 
incremental MUNE was found to have excellent 
test-retest reliability, and to decline monotonically 
in ALS faster than other measures traditionally used 
in ALS clinical trials. The technique can be well 
standardized, is performed briefl y with good patient 
tolerance, and has a low computational burden. 
Using rate of decline as well as variability, hypo-
thetical power analyses suggested that this measure 
might reduce both sample size and study duration 
in phase II trials. Other new MUNE methods, 
including MUNIX (90) and Bayseian MUNE 
(91,92) are also being developed. While no physio-
logical method of motor unit number estimation has 
been validated against anatomical motor unit counts, 
their use as potential endpoints in clinical trials 
shows great promise. 
 Transcranial magnetic stimulation 
 ALS is diagnosed clinically by the presence of both 
UMN and LMN damage. While LMN abnormali-
ties can be confi rmed objectively using peripheral 
electrodiagnostic methods, UMN fi ndings lack com-
parable established objective markers. Transcranial 
magnetic stimulation (TMS) is a neurophysiological 
test that measures UMN functional integrity, and 
can detect abnormalities when there are no clinical 
UMN signs. TMS works by evoking compound 
motor potentials (MEP) using non-invasive mag-
netic stimulation of the motor cortex through activa-
tion of both UMN and LMN pathways. It is used to 
study the conductivity and excitability of the corti-
cospinal system. As potential physiological biomark-
ers, TMS measurements refl ect the functional 
integrity of the UMN (93). 
 Single pulse TMS is a well established diagnos-
tic and clinical research tool, although results vary 
widely between medical centers. However, if indi-
vidual laboratories establish their own normative 
data, subjects can be tested in a consistent, reliable 
fashion. TMS recordings include measurements of 
motor threshold, central motor conduction time, 
and MEP amplitudes, all of which may be abnor-
mal in ALS (94). TMS also can be delivered in 
paired pulses, or as repetitive trains of stimulation 
for investigating human brain function, transiently 
stimulating or inhibiting different cortical areas 
(95,96). 
 TMS biomarkers, particularly single pulse evoked 
TMS amplitude, have been used to objectively dis-
criminate ALS from controls and assess the progres-
sion of ALS (97  –  99). TMS can reveal subtle 
subclinical UMN dysfunction to help make the diag-
nosis of ALS as well as clarify the relationship 
between ALS and its variants (100), including pro-
gressive muscular atrophy where there may be sub-
clinical UMN changes. 
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 Electrical impedance myography 
 Electrical impedance myography (EIM) is a tech-
nique in which a high-frequency, low-intensity elec-
trical current is applied to a localized area of muscle 
and the consequent surface voltages measured (101). 
Unlike standard electromyography, in which the 
intrinsic electrical activity of muscle is measured, 
EIM assesses the integrity and structure of the mus-
cle. An initial, single-center study demonstrated 
EIM ’ s potential power at measuring disease progres-
sion in this disease (102). Recently, a second 
multicenter study compared EIM directly to the 
ALSFRS-R, MUNE, and handheld dynamometry 
(103). EIM outperformed the other measures in 
terms of its ability to detect deterioration. For exam-
ple, based on these data, a study that would require 
220 subjects using the ALSFRS-R would have the 
same power as one with only 95 using EIM. Studies 
in ALS rats have similarly showed a strong correla-
tion to the rate of change in EIM and the animal ’ s 
length of survival, as well as to MUNE (104). The 
methodology is also being applied in the fi rst North 
American study of neural stem cells in ALS (105). 
One advantage of EIM over most other modalities is 
its ability to assess a variety of muscles and to mea-
sure specifi cally that area of the body where the dis-
ease is progressing most rapidly. Measurement of 
other muscles not routinely studied but which might 
provide valuable data, such as paraspinal muscles 
and the tongue, is also possible. Current efforts are 
geared toward further refi ning the technique for easy 
use and making it widely available (106). 
 Neuroimaging biomarker sources 
 MRI has a major role in the exclusion of cerebral, 
and particularly spinal mimics of ALS (107). How-
ever, neuroimaging is also at the forefront of advances 
in the understanding of in vivo cerebral disease 
mechanisms in ALS, including rodent models (108), 
with the identifi cation of multiple candidate bio-
markers as a result (109). 
 Radionuclide imaging 
 Single photon emission computed tomography 
(SPECT) is a practical and potentially widely appli-
cable form of radionuclide imaging. It was at the 
forefront of the recognition of a clinical, pathological 
and, most recently, genetic continuum between ALS 
and frontotemporal dementia (FTD) (110). Posi-
tron emission tomography (PET) has greater resolu-
tion than SPECT but is limited by the availability of 
experienced facilities. Pivotal  ‘ activation ’ PET stu-
dies, using tracers sensitive to blood fl ow and meta-
bolism (e.g. radiolabelled water and fl urodeoxyglucose, 
FDG), provided in vivo evidence for a consistent 
extramotor cerebral pathology in ALS (111). Subse-
quently,  ‘ ligand ’ PET has been used to identify 
specifi c cerebral neuronal receptor changes in ALS. 
Such studies have provided evidence for a loss of 
cortical inhibition (112) that might infl uence pro-
gression rate (113), widespread microglial activation 
(114), and a striking reduction in serotonin-1A 
receptor binding (115), similar to changes seen in 
FTD (116). The future value of PET in ALS will 
depend upon the development of ligands with rele-
vance to pathogenic hypotheses, e.g. glutamate 
receptors, and more specifi c neuroinfl ammatory 
or protein markers, e.g. TDP-43 (the challenge of 
intracellular penetration notwithstanding). 
 Magnetic resonance imaging (MRI) 
 The observation of corticospinal tract hyperintensity 
lacks sensitivity and specifi city for the diagnosis of 
ALS. Routine clinical structural imaging of the brain 
has limited value as a source of biomarkers in ALS, 
and only through advanced analysis methods (117). 
The acquisition of high-resolution 3D T1-weighted 
images and the development of novel pulse sequences 
such as diffusion tensor imaging and functional MRI 
have greatest potential in this regard, and would ulti-
mately be feasible to perform within the clinical envi-
ronment (118). 
 Macroscopic atrophy of the motor cortex is not 
a consistent observation in ALS, although prominent 
in those with PLS. Sophisticated analysis of 3D 
T1-weighted structural images acquired in 3D, 
known as voxel-based morphometry (VBM), can 
reveal subtle changes in regional cerebral tissue. Sev-
eral VBM studies have been performed in ALS, and 
meta-analysis showed the right precentral gyrus as 
consistently altered (119). Surface-based morphom-
etry allows assessment of cortical thickness, and a 
study in ALS confi rmed not only primary motor, but 
also extramotor, temporal cortical thinning in faster 
progressors (120). 
 Post mortem histopathological study fi rst dem-
onstrated widespread cerebral white matter tract 
damage in ALS (121) and this can now be detected 
non-invasively using diffusion tensor imaging (DTI). 
This advanced MRI technique is sensitive to the 
movement of water, normally directionally confi ned 
within neuronal tracts. The two main quantitative 
measures of loss of neuronal tract integrity are 
reduced fractional anisotropy (FA) and increased 
mean diffusivity. Related parameters such as 
increased radial diffusi vity may specifi cally refl ect 
secondary demyelination of tracts in ALS. DTI stud-
ies have shown consistently reduced FA in the cor-
ticospinal tract, particularly within the posterior limb 
of the internal capsule (PLIC) (122) and corpus cal-
losum (123) of ALS patients. Targeted FA measure-
ment at the PLIC may provide prognostic information 
(124). DTI measures may, however, be insuffi ciently 
sensitive to longitudinal change over less than six 
months (125), nor have suffi cient discriminatory 
power as an isolated measurement (126). 
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 MRI is unsurpassed in its spatial resolution of 
cerebral functional activity achieved non-invasively. 
Blood oxygenation level-dependent (BOLD) func-
tional MRI (fMRI) studies of motor tasks in ALS 
patients confi rmed the widened region of activation 
observed in PET studies. More recently, however, 
it is the study of the  ‘ resting state ’ that provides 
novel insight into ALS as a  ‘ system failure ’ . Rest-
ing-state fMRI (R-fMRI) has demonstrated 
increased functional connectivity within the dam-
aged ALS cortical network, with possible implica-
tions in relation to cortical inhibitory infl uences 
(127). The combination of structural and func-
tional MRI measures in this study also provided 
much better separation of patients from healthy 
age-matched controls. 
 Magnetic resonance spectroscopy (MRS) is an 
application of MRI that permits quantifi cation of 
cerebral tissue metabolites. It has consistently dem-
onstrated reduced N-acetylaspartate ratios (a non-
specifi c marker of neuronal loss) in the motor 
cortex of ALS patients, and high-fi eld studies also 
suggest a specifi c loss of GABA-ergic infl uence 
(128). Recent studies applied to the cervical spinal 
cord of pre-symptomatic carriers of pathological 
SOD1 gene mutations demonstrated metabolite 
changes more consistent with affected ALS patients 
rather than healthy non-gene carriers (129), sug-
gesting that MRS may be particularly sensitive to 
pre-clinical changes. This offers the hope of captur-
ing the very earliest events in individuals carrying 
genetic abnormalities associated with the develop-
ment of ALS, with the possibility of wider transla-
tion to sporadic cases. 
 The challenge for neuroimaging biomarker can-
didates is to move beyond results based on group 
averages, to individual measurements. It seems likely 
that this will require multiple parameters. Further 
longitudinal studies are needed to assess the sensi-
tivity of multimodal MRI to disease activity com-
pared to clinical assessments such as ALSFRS. 
 Concluding remarks 
 Major advances in the understanding of the patho-
biology of ALS have occurred over the last two 
decades with developments in molecular biology, 
immunocytochemistry, neurophysiology and neu-
roimaging, and the recognition of overlap with 
some forms of FTD. It seems increasingly likely 
that there are multiple, possibly more discrete, 
pathways converging on motor neuron death. While 
recent discoveries in relation to RNA biology hint 
at a massively under-estimated level of pathologi-
cal complexity in ALS, the common theme of mis-
folded protein inclusions across the range of 
neurodegenerative disorders brings the hope of a 
common strategy for the treatment of pre-aggrega-
tion events (130) and for common biomarker 
development. Biomarker candidates are emerging 
with the potential to refi ne the diagnosis, stratify 
patients prognostically, and facilitate therapeutic 
development. A key aim for further biomarker 
development, beyond validation across multiple 
centers, is the routine incorporation of biomarker 
measurement into future clinical trials. 
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